Long-term oral antibiotic treatment: why, what, when and to whom? Source: Eur Respir Monogr 2017; 75: 185-205 Year: 2017
Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Source: Eur Respir J 2013; 42: 1449-1453 Year: 2013
Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: is “blind” treatment dangerous? Source: Eur Respir J 2011; 37: 1283-1285 Year: 2011
Drug resistant tuberculosis: is it enough to justify low treatment success in Russia? Source: Eur Respir J 2001; 18: Suppl. 33, 175s Year: 2001
Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Rifampicin-resistant TB on Gene Xpert: What is the best empiric combination treatment while awaiting cultures? Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Do we need to screen for latent TB when initiating a methotrexate treatment? Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013
Could side effects of MDR-TB treatment change the outcome of the disease? Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Treatment interruptions in patients with MDR/XDR-TB: risk factors and impact on treatment outcomes Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016
Intermittent regimens for tuberculosis treatment: Back to the Future? Source: Eur Respir J, 56 (3) 2002510; 10.1183/13993003.02510-2020 Year: 2020
Is there a need for prolonged follow up in mono-drug resistant TB? Source: International Congress 2014 – Tuberculosis: epidemiology and public health Year: 2014
Therapeutic strategies in pneumonia: going beyond antibiotics Source: Eur Respir Rev 2015; 24: 516-524 Year: 2015
Evaluating disease-modifying treatment in CF: are we ready to take the challenge? Source: International Congress 2014 – Ceremony for the ERS Rare Pulmonary Disease Research Award 2014 followed by the symposium "Challenges in endpoints for rare lung diseases" Year: 2014
Macrolide therapy in asthma: limited treatment, long-term improvement Source: Eur Respir J 2009; 33: 1239 Year: 2009
Tuberculosis elimination, patients' lives and rational use of new drugs: revisited Source: Eur Respir J 2016; 47: 664-667 Year: 2016
Is empirical antibiotic treatment correlated to outcome in microbiology-negative pleural infection? Source: International Congress 2016 – Severe respiratory infections in the intensive care unit and pleural and fungal infections Year: 2016
New short regimens for latent tuberculosis treatment: safety first! Source: Eur Respir J, 52 (6) 1802180; 10.1183/13993003.02180-2018 Year: 2018